Helical dual-phase CT scan in evaluating blood supply of primary heptocellular carcinoma after transcatheter hepatic artery chemoembolization with lipiodol.
- Author:
Li-lian TAN
1
;
Yang-bin LI
;
De-ji CHEN
;
Shu-xin LI
;
Jin-dai JIANG
;
Zhi-ming LI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; Contrast Media; Female; Hepatic Artery; Humans; Iodized Oil; Liver Neoplasms; diagnostic imaging; therapy; Male; Middle Aged; Tomography, Spiral Computed
- From: Chinese Journal of Oncology 2003;25(1):82-84
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the blood supply of low density viable area of primary heptocellular carcinoma after transcatheter hepatic artery chemoembolization using lipiodol (LP-TACE), by helical dual-phase CT scanning and three dimensional CT (3DCT).
METHODSThirty-four patients with primary heptocellular carcinoma after LP-TACE were examined by hepatic helical dual-phase CT. 3DCT model of the maximum intensity projection (MIP), surface shaded display (SSD) reconstruction of the hepatic artery and portal vein were simultaneously done in 5 cases.
RESULTSViable tumor areas of 34 cases of primary heptocellular carcinoma after LP-TACE were divided into four types: peripheral, lateral, central and diffused types. Enhanced tumor vessel or tissue in viable tumor area was found during hepatic dual-phase in 17 cases, during hepatic artery-phase only in 8 and hepatic portal vein-phase only in 3. The viable tumor areas were found to have blood supply from the hepatic vein in 2 cases. The viable tumor area unenhanced during hepatic dual-phase was found in 6 cases. In 5 cases, the relation between the viable tumor area and branches of hepatic artery and portal vein was showed by MIP and SSD of hepatic artery and portal vein.
CONCLUSIONHepatic helical dual-phase CT scan with 3DCT is effective in evaluating the blood supply of viable tumor areas and the therapeutic effect of primary heptocellular carcinoma after LP-TACE.